Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]P17-059 PET Imaging in Parkinson's Disease
NCT03903549Phase 1Completed
- Sponsor
- Five Eleven Pharma, Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Fluorine-18 P17-059 (3 arms), sponsored by Five Eleven Pharma, Inc. Primary endpoints: Regional brain uptake of [18F]P17-059 in Parkinson patients compared to healthy volunteers and Cumulative organ [18F]P17-059 activity for estimates of radiation absorbed dose and effective dose. Started Jul 2022; status: completed.
02
Drugs
Fluorine-18 P17-059
Beyond the preview
Go deeper on NCT03903549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903549.